Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,424
archived clinical trials in
Cognitive Studies

Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Saint John's Hospital - Healtheast
1402
mi
from 98109
Maplewood, MN
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Saint John's Hospital - Healtheast
1402
mi
from 98109
Maplewood, MN
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Abbott Northwestern Hospital
1388
mi
from 98109
Minneapolis, MN
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Abbott Northwestern Hospital
1388
mi
from 98109
Minneapolis, MN
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Hennepin County Medical Center
1393
mi
from 98109
Minneapolis, MN
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Hennepin County Medical Center
1393
mi
from 98109
Minneapolis, MN
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
North Memorial Medical Health Center
1387
mi
from 98109
Robbinsdale, MN
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
North Memorial Medical Health Center
1387
mi
from 98109
Robbinsdale, MN
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
1450
mi
from 98109
Rochester, MN
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
1450
mi
from 98109
Rochester, MN
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Coborn Cancer Center at Saint Cloud Hospital
1336
mi
from 98109
Saint Cloud, MN
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Coborn Cancer Center at Saint Cloud Hospital
1336
mi
from 98109
Saint Cloud, MN
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Metro Minnesota Community Oncology Research Consortium
1388
mi
from 98109
Saint Louis Park, MN
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Metro Minnesota Community Oncology Research Consortium
1388
mi
from 98109
Saint Louis Park, MN
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Park Nicollet Clinic - Saint Louis Park
1388
mi
from 98109
Saint Louis Park, MN
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Park Nicollet Clinic - Saint Louis Park
1388
mi
from 98109
Saint Louis Park, MN
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Regions Hospital
1399
mi
from 98109
Saint Paul, MN
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Regions Hospital
1399
mi
from 98109
Saint Paul, MN
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Saint Francis Regional Medical Center
1383
mi
from 98109
Shakopee, MN
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Saint Francis Regional Medical Center
1383
mi
from 98109
Shakopee, MN
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Rice Memorial Hospital
1305
mi
from 98109
Willmar, MN
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Rice Memorial Hospital
1305
mi
from 98109
Willmar, MN
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Minnesota Oncology and Hematology PA-Woodbury
1407
mi
from 98109
Woodbury, MN
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Minnesota Oncology and Hematology PA-Woodbury
1407
mi
from 98109
Woodbury, MN
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Montana Cancer Consortium NCORP
667
mi
from 98109
Billings, MT
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Montana Cancer Consortium NCORP
667
mi
from 98109
Billings, MT
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Billings Clinic Cancer Center
668
mi
from 98109
Billings, MT
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Billings Clinic Cancer Center
668
mi
from 98109
Billings, MT
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Nebraska Cancer Research Center
1350
mi
from 98109
Lincoln, NE
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Nebraska Cancer Research Center
1350
mi
from 98109
Lincoln, NE
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Missouri Valley Cancer Consortium
1366
mi
from 98109
Omaha, NE
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Missouri Valley Cancer Consortium
1366
mi
from 98109
Omaha, NE
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Alegent Health Immanuel Medical Center
1358
mi
from 98109
Omaha, NE
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Alegent Health Immanuel Medical Center
1358
mi
from 98109
Omaha, NE
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Alegent Health Bergan Mercy Medical Center
1362
mi
from 98109
Omaha, NE
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Alegent Health Bergan Mercy Medical Center
1362
mi
from 98109
Omaha, NE
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Alegent Health Lakeside Hospital
1366
mi
from 98109
Omaha, NE
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Alegent Health Lakeside Hospital
1366
mi
from 98109
Omaha, NE
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences
2279
mi
from 98109
Winston-Salem, NC
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences
2279
mi
from 98109
Winston-Salem, NC
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Sanford Clinic North-Fargo
1194
mi
from 98109
Fargo, ND
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Sanford Clinic North-Fargo
1194
mi
from 98109
Fargo, ND
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Foundation
2016
mi
from 98109
Cleveland, OH
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Foundation
2016
mi
from 98109
Cleveland, OH
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
University of Pennsylvania:Abramson Cancer Center
2371
mi
from 98109
Philadelphia, PA
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
University of Pennsylvania:Abramson Cancer Center
2371
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Cancer Institute (UPCI)
2135
mi
from 98109
Pittsburgh, PA
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Cancer Institute (UPCI)
2135
mi
from 98109
Pittsburgh, PA
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Geisinger Wyoming Valley/Henry Cancer Center
2301
mi
from 98109
Wilkes-Barre, PA
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Geisinger Wyoming Valley/Henry Cancer Center
2301
mi
from 98109
Wilkes-Barre, PA
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Sanford USD Medical Center - Sioux Falls
1263
mi
from 98109
Sioux Falls, SD
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Sanford USD Medical Center - Sioux Falls
1263
mi
from 98109
Sioux Falls, SD
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
2485
mi
from 98109
Boston, MA
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Hawaii Cancer Care Inc-POB II
2679
mi
from 98109
Honolulu, HI
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Hawaii Cancer Care Inc-POB II
2679
mi
from 98109
Honolulu, HI
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Hawaii Oncology Inc-Kuakini
2677
mi
from 98109
Honolulu, HI
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Hawaii Oncology Inc-Kuakini
2677
mi
from 98109
Honolulu, HI
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - Wichita
1435
mi
from 98109
Wichita, KA
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - Wichita
1435
mi
from 98109
Wichita, KA
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Saint Vincent Hospital Cancer Center Green Bay
1646
mi
from 98109
Green Bay, WI
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Saint Vincent Hospital Cancer Center Green Bay
1646
mi
from 98109
Green Bay, WI
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Saint Vincent Hospital Cancer Center at Saint Mary's
1642
mi
from 98109
Green Bay, WI
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Saint Vincent Hospital Cancer Center at Saint Mary's
1642
mi
from 98109
Green Bay, WI
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Hawaii Oncology Inc-Pali Momi
2678
mi
from 98109
'Aiea, HI
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Hawaii Oncology Inc-Pali Momi
2678
mi
from 98109
'Aiea, HI
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Pali Momi Medical Center
2678
mi
from 98109
'Aiea, HI
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Pali Momi Medical Center
2678
mi
from 98109
'Aiea, HI
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Sanford Broadway Medical Center
1194
mi
from 98109
Fargo, ND
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Sanford Broadway Medical Center
1194
mi
from 98109
Fargo, ND
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Emory University Hospital-Winship Cancer Institute
2178
mi
from 98109
Atlanta, GA
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Emory University Hospital-Winship Cancer Institute
2178
mi
from 98109
Atlanta, GA
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
McFarland Clinic PC - Ames
1450
mi
from 98109
Ames, IA
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
McFarland Clinic PC - Ames
1450
mi
from 98109
Ames, IA
Click here to add this to my saved trials
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Sanford Joe Lueken Cancer Center
1273
mi
from 98109
Bemidji, MN
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Sanford Joe Lueken Cancer Center
1273
mi
from 98109
Bemidji, MN
Click here to add this to my saved trials
A Controlled Trial of Serotonin Reuptake Inhibitors Added to Stimulant Medication in Youth With Severe Mood Dysregulation
A Controlled Trial of Citalopram Added to Methylphenidate in Youth With Severe Mood Dysregulation
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
2315
mi
from 98109
Bethesda, MD
A Controlled Trial of Serotonin Reuptake Inhibitors Added to Stimulant Medication in Youth With Severe Mood Dysregulation
A Controlled Trial of Citalopram Added to Methylphenidate in Youth With Severe Mood Dysregulation
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
2315
mi
from 98109
Bethesda, MD
Click here to add this to my saved trials
Pharmacological Management of Delirium
Pharmacological Management of Delirium
Status: Enrolling
Updated:  12/31/1969
Eskenazi Hospital
1867
mi
from 98109
Indianapolis, IN
Pharmacological Management of Delirium
Pharmacological Management of Delirium
Status: Enrolling
Updated: 12/31/1969
Eskenazi Hospital
1867
mi
from 98109
Indianapolis, IN
Click here to add this to my saved trials
Pharmacological Management of Delirium
Pharmacological Management of Delirium
Status: Enrolling
Updated:  12/31/1969
Methodist Hospital
1867
mi
from 98109
Indianapolis, IN
Pharmacological Management of Delirium
Pharmacological Management of Delirium
Status: Enrolling
Updated: 12/31/1969
Methodist Hospital
1867
mi
from 98109
Indianapolis, IN
Click here to add this to my saved trials
Pharmacological Management of Delirium
Pharmacological Management of Delirium
Status: Enrolling
Updated:  12/31/1969
University Hospital
1851
mi
from 98109
Indianapolis, IN
Pharmacological Management of Delirium
Pharmacological Management of Delirium
Status: Enrolling
Updated: 12/31/1969
University Hospital
1851
mi
from 98109
Indianapolis, IN
Click here to add this to my saved trials
Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders
Pharmacotherapy of Pervasive Developmental Disorders
Status: Enrolling
Updated:  12/31/1969
Riley Hospital for Children, Christian Sarkine Autism Treatment Center
1867
mi
from 98109
Indianapolis, IN
Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders
Pharmacotherapy of Pervasive Developmental Disorders
Status: Enrolling
Updated: 12/31/1969
Riley Hospital for Children, Christian Sarkine Autism Treatment Center
1867
mi
from 98109
Indianapolis, IN
Click here to add this to my saved trials
PANDA (Pediatric Anesthesia & NeuroDevelopment Assessment) Study
Anesthesia Exposure and Neurodevelopment in Infants and Children: Pediatric Anesthesia & NeuroDevelopment (PANDA) Study
Status: Enrolling
Updated:  12/31/1969
Columbia University, 622 W. 168th St.
2401
mi
from 98109
New York, NY
PANDA (Pediatric Anesthesia & NeuroDevelopment Assessment) Study
Anesthesia Exposure and Neurodevelopment in Infants and Children: Pediatric Anesthesia & NeuroDevelopment (PANDA) Study
Status: Enrolling
Updated: 12/31/1969
Columbia University, 622 W. 168th St.
2401
mi
from 98109
New York, NY
Click here to add this to my saved trials
PANDA (Pediatric Anesthesia & NeuroDevelopment Assessment) Study
Anesthesia Exposure and Neurodevelopment in Infants and Children: Pediatric Anesthesia & NeuroDevelopment (PANDA) Study
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Philadelphia
2373
mi
from 98109
Philadelphia, PA
PANDA (Pediatric Anesthesia & NeuroDevelopment Assessment) Study
Anesthesia Exposure and Neurodevelopment in Infants and Children: Pediatric Anesthesia & NeuroDevelopment (PANDA) Study
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Philadelphia
2373
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
PANDA (Pediatric Anesthesia & NeuroDevelopment Assessment) Study
Anesthesia Exposure and Neurodevelopment in Infants and Children: Pediatric Anesthesia & NeuroDevelopment (PANDA) Study
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center
1971
mi
from 98109
Nashville, TN
PANDA (Pediatric Anesthesia & NeuroDevelopment Assessment) Study
Anesthesia Exposure and Neurodevelopment in Infants and Children: Pediatric Anesthesia & NeuroDevelopment (PANDA) Study
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center
1971
mi
from 98109
Nashville, TN
Click here to add this to my saved trials
PANDA (Pediatric Anesthesia & NeuroDevelopment Assessment) Study
Anesthesia Exposure and Neurodevelopment in Infants and Children: Pediatric Anesthesia & NeuroDevelopment (PANDA) Study
Status: Enrolling
Updated:  12/31/1969
Children's Hospital Boston
2484
mi
from 98109
Boston, MA
PANDA (Pediatric Anesthesia & NeuroDevelopment Assessment) Study
Anesthesia Exposure and Neurodevelopment in Infants and Children: Pediatric Anesthesia & NeuroDevelopment (PANDA) Study
Status: Enrolling
Updated: 12/31/1969
Children's Hospital Boston
2484
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Prevalence and Predictors of Neurocognitive Impairment Among HIV-infected Patients
Prevalence and Predictors of Neurocognitive Impairment Among HIV-infected Patients
Status: Enrolling
Updated:  12/31/1969
Naval Medical Center - San Diego
1077
mi
from 98109
San Diego, CA
Prevalence and Predictors of Neurocognitive Impairment Among HIV-infected Patients
Prevalence and Predictors of Neurocognitive Impairment Among HIV-infected Patients
Status: Enrolling
Updated: 12/31/1969
Naval Medical Center - San Diego
1077
mi
from 98109
San Diego, CA
Click here to add this to my saved trials
Prevalence and Predictors of Neurocognitive Impairment Among HIV-infected Patients
Prevalence and Predictors of Neurocognitive Impairment Among HIV-infected Patients
Status: Enrolling
Updated:  12/31/1969
Walter Reed National Military Medical Center
2316
mi
from 98109
Bethesda, MD
Prevalence and Predictors of Neurocognitive Impairment Among HIV-infected Patients
Prevalence and Predictors of Neurocognitive Impairment Among HIV-infected Patients
Status: Enrolling
Updated: 12/31/1969
Walter Reed National Military Medical Center
2316
mi
from 98109
Bethesda, MD
Click here to add this to my saved trials
Prevalence and Predictors of Neurocognitive Impairment Among HIV-infected Patients
Prevalence and Predictors of Neurocognitive Impairment Among HIV-infected Patients
Status: Enrolling
Updated:  12/31/1969
Brooke Army Medical Center
1786
mi
from 98109
Fort Sam Houston, TX
Prevalence and Predictors of Neurocognitive Impairment Among HIV-infected Patients
Prevalence and Predictors of Neurocognitive Impairment Among HIV-infected Patients
Status: Enrolling
Updated: 12/31/1969
Brooke Army Medical Center
1786
mi
from 98109
Fort Sam Houston, TX
Click here to add this to my saved trials